tbuckley/cabot-search huggingface dataset:
GSH Activated Biotin-tagged Near-Infrared Probe for Efficient Cancer Imaging
Authors: Ruiying Guo, Feng Huang, Bo Zhang, Youyou Yan, Jinxin Che, Yizhen Jin, Yuxin Zhuang, Rong Dong, Yangling Li, Biqin Tan, Rui Song, Yongzhou Hu, Xiaowu Dong, Xin Li, Nengming Lin
Journal: Theranostics (2019)

Tumor imaging tools with high specificity and sensitivity are needed to aid the boundary recognition in solid tumor diagnosis and surgical resection.In this study, we developed a near infra-red (NIR) probe (P6) for in vitro/in vivo tumor imaging on the basis of the dual strategy of cancer cell targeting and stimulus-dependent activation.The selective imaging capacity towards cancer cells of P6 was thoroughly investigated, and the potential mechanisms of endocytosis were preliminary explored.Methods: GSH-activated biotin labelled NIR probe (P6) was designed, synthesized and characterized.The GSH responsive properties were systematically illustrated through UV-vis, fluorescent tests and LC-MS analysis.In vitro fluorescent imaging of probe P6 was collected in various living cancer cell lines (i.e.SW480, HGC-27, H460, BxPC-3, KHOS) and normal cell lines (i.e.BEAS-2B, HLF-1, THP1) under confocal laser scanning microscopy.Probe P6 was further applied to image primary human cancer cells which were freshly isolated from the peritoneal carcinoma and rectal cancer patients.Serial sections of human tumor tissues were collected and sent for H&E (hematoxylin-eosin) staining and P6 imaging.Live fluorescent and photoacoustic imaging were used to investigate the in vivo imaging of P6 in both tumor and normal tissues in HGC-27 and KHOS xenograft model.Results: Probe P6 could be recognized and transported into cancer cells by tumor specific biotin receptors and efficiently be triggered by GSH to release fluorophore 4. In fact, the cellular uptake of P6 could be partially blocked by the addition of free biotin.Furthermore, probe P6 could image various cancer cell lines, as well as primary cancer cells, exhibiting a ten-fold increase in fluorescence intensity over normal cells.In freshly dissected cancer tissues, P6 fluorescent imaging distinguished the cancerous area under confocal laser scanning microscopy, which was exact the same area as indicated by H&E staining.We also found that P6 exhibited superior selectivity against cancer tissues by local injection. Conclusion:In this study, we developed a dual-modal NIR probe P6 with enhanced cellular uptake into cancer cells and environmental stimulus triggered fluorescence.Our strategy provided a novel insight into the development of imaging tools that could be potentially used for fluorescent image-guided cancer boundary recognition and possibly cancer diagnosis.
Two Different Platelet Thresholds for Bleeding Prophylaxis in Children with Malignancies or Non-Malignant Disorders: The Bambino Gesù Children's Hospital Experience
Authors: Pierpaolo Berti, Guglielmo Trua, Francesco Lamura, Laila Costantino, Costantino Damico, Alessandra Paoloni, Maria Teresa Romano, Katia Girardi, Luisa Strocchio, Elisabetta Cicchetti, Alessandra Bernardi, Valentina De Nava, Antonio Cappelli, Andrea Onetti Muda, Mauro Montanari
Journal: Blood (2019)
Diabetes Mellitus and Pernicious Anaemia
Authors: A. G. Stewart
Journal: BMJ (1963)

with his whole body in the lateral position), and with the attendant's four fingers of the more convenient hand slightly cupped, and applied to the under surface of the chin, pulling it gently forward in such a way that each breath can be felt on the palm of the hand.Very little pressure is needed, and the method is easily learned in a few minutes even by a beginner.Immediate warning is given should respiration cease or even become shallow, and only one hand is used.I always demonstrate to each new group of nurses how chest movement per se means only that the patient is attempting respiration, not necessarily breathing-a fact known to all anaesthetists but usually kept a carefully guarded secret.-I am, etc.,
Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents
Authors: Bo Angela Wan, Richard A. Wells, Lisa Chodirker, Ken Rockwood, Michelle Geddes, Nancy Zhu, Grace Christou, Mitchell Sabloff, Mary-Margaret Keating, Brian Leber, Heather A. Leitch, Karen W.L. Yee, Eve St-Hilaire, Nicholas Finn, John Storring, Thomas J. Nevill, April Shamy, Versha Banerji, Mohamed Elemary, Robert Delage, Alexandre Mamedov, Martha Lenis, Liying Zhang, Aksharh Kirubananthaan, Shabbir Alibhai, Rena Buckstein
Journal: Blood (2019)
Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)
Authors: Herve Ghesquieres, Olivier Casasnovas, Emmanuelle Nicolas-Virelizier, Damaj Gandhi Laurent, Vincent Delwail, Mohamed Touati, Katell Le Du, Franck Morschhauser, Christophe Bonnet, Agathe Waultier-Rascalou, Frederique Orsini-Piocelle, Marc André, Myriam Ben Boutieb, Fabienne Morand, Diane Damotte, Alexandra Traverse-Glehen, Philippe Quittet, Pauline Brice
Journal: Blood (2019)
Liver Is a Generative Site for the B Cell Response to Ehrlichia muris
Authors: Nikita Trivedi, Florian Weisel, Shuchi Smita, Stephen Joachim, Muhamuda Kader, Aditya Radhakrishnan, Chris Clouser, Aaron M. Rosenfeld, Maria Chikina, Francois Vigneault, Uri Hershberg, Nahed Ismail, Mark Jay Shlomchik
Journal: Immunity (2019)
Assessment of Different Biological Variables (Serum Albumin, β-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a Retrospective Cohort of 525 Diffuse Large B-Cell Lymphomas As Predictor Factor(s) for Overall Survival
Authors: Luis Villela M, Ana Ramirez-Ibarguen, Brady E. Beltrán, Victoria Otero, Denisse A. Castro, Myrna Candelaria, Fernando Pérez-Jacobo, Efreen Montaño Figueroa, Camila Peña, Sally Rose Paredes, Carlos Best, Andrés Gómez-De León, David Gomez-Almaguer, Guillermo J. Ruiz-Arguelles, Henry Idrobo, Virginia Abello, Pilar León, Jose A Hernández-Hernández, Yocanxochitl Perfecto, Melani Otañez, Sergio Tena, Silvia Rivas-Vera, Luis E Malpica Castillo, Eduardo Sotomayor, Jorge J. Castillo
Journal: Blood (2019)
Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone
Authors: Slavisa Ninkovic, Simon Harrison, Lenny Straszkowski, Giulia Quattrocchi, Wee-Joo Chng, Louise E Purton, Hang Quach
Journal: Blood (2019)
STEM-22. TARGETING PYRIMIDINE SYNTHESIS ACCENTUATES MOLECULAR THERAPY RESPONSE IN GLIOBLASTOMA STEM CELLS
Authors: Kailin Yang, Xiuxing Wang, Qiulian Wu, Leo Kim, Andrew Morton, Ryan Gimple, Briana Prager, Yu Shi, Wenchao Zhou, Shruti Bhargava, Zhe Zhu, Li Jiang, Weiwei Tao, Zhixin Qiu, Linjie Zhao, Guoxing Zhang, Xiqing Li, Sameer Agnihotri, Paul Mischel, Stephen Mack, Shideng Bao, Jeremy Rich
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma stem cells (GSCs) reprogram glucose metabolism by hijacking high-affinity glucose uptake to survive in a nutritionally dynamic microenvironment. Here, we trace metabolic aberrations in GSCs to link core genetic mutations in glioblastoma to dependency on de novo pyrimidine synthesis. Targeting the pyrimidine synthetic rate-limiting step enzyme carbamoyl-phosphate synthetase 2, aspartate transcarbamyolase, dihydroorotase (CAD) or the critical downstream enzyme, dihydroorotate dehydrogenase (DHODH) inhibited GSC survival, self-renewal, and in vivo tumor initiation through the depletion of the pyrimidine nucleotide supply in rodent models. Mutations in EGFR or PTEN generated distinct CAD phosphorylation patterns to activate carbon influx through pyrimidine synthesis. Simultaneous abrogation of tumor-specific driver mutations and DHODH activity with clinically approved inhibitors demonstrated sustained inhibition of metabolic activity of pyrimidine synthesis and GSC tumorigenic capacity. Higher expression of pyrimidine synthesis genes portend poor prognosis of glioblastoma patients. Collectively, our results demonstrate a therapeutic approach of precision medicine through targeting the nexus between driver mutations and metabolic reprogramming in cancer stem cells.
Platelet Adherence to Polymorphs
Authors: E. J. Field, I. MacLeod
Journal: BMJ (1963)

MMICJOwMUA tion period longer than that of viral respiratory tract infections, severe pneumonia lasting more than a week, diaphoresis, low leucocytosis, cold- agglutination of erythrocytes, and pleural sequels had the earmarks of what is now known as Mycoplasma pneumoniae (Eaton agent) pneumonia5 and which, indeed, is a non-viral primary " atypical " pneumonia.There is no reason to believe that it is a "new" disease.It is a newly delineated one.Aitiological studies of nasopharyngeal washings from two patients were made in 1938 by Francis and Magill' and inde- pendently by Stokes, Kenney, and Shaw.7 Cultures disclosed no known pathogen, but at that time no one suspected or looked for mycoplasma (P.P.L.O.) as a possible.cause.An agent was recovered that passed through a Berkefeld V and a 780 mp collodion membrane filter.Intra- nasal inoculation of ferrets caused no disease, but further transfer intranasally or intracerebrally in mice and guinea-pigs caused monocytic pneumonia, toxic de- generation of the brain, and paresis after seven to ten days.During the first few passages most of the mice died; in subse- quent passage the agent lost virulence and vanished.It may have been an un- recognized mycoplasma.-Iam, etc.,
Genetics of Human Thyroid Cancer Cell Lines—Letter
Authors: Cyril Garcia, Françoise Cormier, Lionel Groussin
Journal: Clinical Cancer Research (2019)

We read with great interest the article by Landa and colleagues that reported the comprehensive genetic characterization of 60 human thyroid cancer cell lines ([1][1]). Molecular driver alterations, similar to known genomic defects in human thyroid cancers, were identified in most of these cell
Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia
Authors: Pinar Ataca Atilla, Haruko Tashiro, Mary Kathryn McKenna, Madhuwanti Srinivasan, Brian Wesley Simons, Alexandra McLean Stevens, Michele Redell, Maksim Mamonkin, Malcolm K. Brenner, Erden Atilla
Journal: Blood (2019)
The Effect of Continuous Screening of Carbapenem-Resistant Enterobacteriaceae on Theprevention and Control of Bloodstream Infections in Patients with Hematopoietic Stemcell Transplantation
Authors: Tingting Yang, Xueping Luo, Qing Yang, Hongchao Chen, Yi Luo, Yanmin Zhao, Xiaoyu Lai, Jian Yu, Yamin Tan, Guoqing Wei, He Huang, Jimin Shi
Journal: Blood (2019)
Arcagen: An EORTC-SPECTA project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort
Authors: M. Vinches, A. Stevovic, I.L. Ray-Coquard, I. Treilleux, P. Meeus, S. Aust, A. Floquet, S. Croce, L. Chalabreysse, N. Girard, J-Y Blay, M. Morfouace
Journal: Annals of Oncology (2019)
Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)
Authors: Alix E. Seif, Yimei Li, Viviane C. Cahen, Yuan-Shung V. Huang, Matt Hall, E. Anders Kolb, Brian T. Fisher, Richard Aplenc, Kelly D Getz
Journal: Blood (2019)
Non-Canonical MYD88/TIRAP-Dependent Anti-Inflammatory Function of Pro-Coagulant Factor VIII
Authors: Sandra Mignot, Sandrine Delignat, Sebastien Lacroix-demaze, Christine Bole-Feysot, Sherine Tei, Ananthy Kiddinan, Olivier Hermine, Laurent Frenzel
Journal: Blood (2019)
Zinc Treatment Stimulates Thymic Regeneration after Bone Marrow Transplant
Authors: Lorenzo Iovino, Sinéad Kinsella, Kirsten Cooper, Reema Jain, Paul DeRoos, Alex Gagnon, Tamas M Ugrai, Gabriele Buda, Sara Galimberti, Mario Petrini, Jarrod A Dudakov
Journal: Blood (2019)
MN1 Expression Is an Indepedent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors
Authors: Diego A Pereira-Martins, Juan L Coelho-Silva, Isabel Weinhäuser, Carol Hassibe Thomé, César Alexander Ortiz Rojas, Luíse A A Simões, Fabiola Traina, Michael Heuser, Arnold Ganser, Antonio R. Lucena-Araujo, Eduardo M Rego
Journal: Blood (2019)
Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
Authors: Christopher Strouse, Sarah C. Rutherford, Brian J Smith, David L. Jaye, Brad S. Kahl, Izidore S. Lossos, Carrie A. Thompson, Jonathan W. Friedberg, Andrew L. Feldman, Carla Casulo, Jonathon B. Cohen, Jennifer R Chapman, Sergei Syrbu, Thomas E. Witzig, Loretta J. Nastoupil, Timothy J. McDonnell, Melissa C Larson, Thomas M. Habermann, Susan L. Slager, Christopher R. Flowers, James R. Cerhan, Peter Martin, Brian K. Link
Journal: Blood (2019)
TMIC-39. DEVELOPMENT OF CD11b TRACER FOR THE IMMUNE PET IMAGING IN GLIOBLASTOMA MODEL - COULD BE A GAME CHANGER FOR IMMUNOTHERAPY APPROACHES
Authors: Shubhanchi Nigam, Lauren McCarl, Rajeev Kumar, Carolyn Anderson, Barry Edwards, Gary Kohanbash
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma is a lethal brain tumor, heavily infiltrated by tumor-associated myeloid cells (TAMCs). As up to 30% of a glioma cellular mass may be attributed to immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). TAMCs impede natural and immunotherapy-driven anti-tumor responses, they are a high-priority and promising therapeutic target currently being evaluated in clinical trials. Multiple preclinical and clinical trials have attempted to target these cells, however monitoring of biologic responses to therapy remains a challenge. Quantifying real time status of MDSCs and TAMs at the tumor site using non-invasive immunoPET could improve therapeutic response and allow for better patient stratification and monitoring of targeted treatment responses. TAMCs highly expressed the cell surface marker, integrin CD11b (Mac-1, αMβ2) and may be a highly effective imaging target for immunoPET strategies. The human/mouse cross-reactive anti-CD11b antibody (clone M1/70) was radiolabeled with 89Zr for PET imaging. PET/CT imaging, with or without a blocking dose of anti-CD11b Ab, was performed in mice bearing established orthotopic syngeneic GL261 gliomas. Flow cytometry and histology in tissues collected from post-imaging biodistribution validated targeting of CD11b+ MDSCs and TAMs. There was significant Zr-89-anti-CD11b Ab uptake in the tumor ipsilateral right brain (SUVmean = 2.6 ± 0.24) compared to contralateral left brain (SUVmean = 0.6 ± 0.11). Blocking with 10-fold lower specific activity 89Zr-anti-CD11b Ab reduced the SUV in right brain with (SUVmean = 0.11 ± 0.06). Immune rich organs spleen and lymph nodes showed high uptake. These results correlated with biodistribution analysis. CD11b expression in the right and left brain were validated using flow cytometry, H&amp;E and IHC, showing high CD11b expression in the right brain. Imaging TAMs and MDSCs with 89Zr-labeled anti-CD11b Ab targeting was validated in a mouse model of malignant gliomas, demonstrating the feasibility of monitoring immune response during immunotherapy.
Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with &gt;18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)
Authors: Jerzy Windyga, Pal A Holme, C. Hermans, Ana R Cid, Nirjhar Chatterjee, Hongyu Jiang, Viridiana Cano-Garcia, Carmen Escuriola
Journal: Blood (2019)
Abstract 3061: Possibilities of Optical Coherence Tomography in identifying vulnerable plaques: a comparison with intravascular ultrasound and coronary angioscopy
Authors: Takashi Kubo, Takashi Masyo, Takashi Yamano, Shigeho Takarada, Yoshiaki Tomobuchi, Takashi Akasaka
Journal: Circulation (2006)

[Background] Optical coherence tomography (OCT) is a new intravascular imaging method with a high resolution of approximately 10–20micrometer, which is 10-fold greater than that of intravascular ul...
Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?.
Authors: Ulrich Keilholz, Anne Letsch, Antonia Busse, Annemarie Asemissen, Igor W. Blau, Wolf K. Hofmann, Lutz Uharek, Eckhard Thiel, Carmen Scheibenbogen
Journal: Blood (2007)
Elevated Serum Soluble Interleukin-2 Receptor Level Is a Useful Prognostic Factor for Disease-Specific Overall Survival in Patients with Newly Diagnosed Follicular Lymphoma before Initiation of Treatment
Authors: Kenji Nozaki, Hiroyuki Sugahara, Shuji Ueda, Jun Ishikawa, Shigeo Fuji, Hiroaki Masaie, Yuma Tada, Makiko Suga, Kazuhito Tsutsumi, Kumi Shibata, Shuhei Kida, Takahiro Karasuno, Hiroshi Sata, Masato Yasumi, Masato Iida, Hideki Mitsui, Tsuyoshi Kamae, Norimitsu Saito, Hiraku Murakami, Yasuhiro Moriyama, Manabu Kawakami, Ruri Kato, Yoshiki Nakae, Toru Kida, Satoru Kosugi, Hirohiko Shibayama
Journal: Blood (2019)
PDTM-44. ROLE OF ONC-206 IN REGULATING MEDULLOBLASTOMA TUMOR PROGRESSION
Authors: Anshu Malhotra, Jingbo Liu, Tobey MacDonald
Journal: Neuro-Oncology (2019)

Abstract Medulloblastoma (MB) is the most common malignant brain tumor in children. Of the four different sub-groups, the Sonic Hedgehog (SHH) subgroup accounts for about 30% of human MBs. The current standard of care (resection, cranio-spinal irradiation, and chemotherapy) for MB is typically ineffective for SHH MB in non-infants and those with metastatic disease. Survivors are frequently beset with long-term side effects including cognitive deficiencies and a severely impaired quality of life. Taken together, there is a critical need for novel targeted therapies for SHH MB. Recently, promising preclinical and clinical results have been obtained in a variety of cancers treated with a small molecule antagonist, ONC-201, which acts against DRD2, a G-protein coupled receptor that is widely expressed in MBs and regulates pro-survival pathways in tumors. In the present study we report the activity of ONC-201 and another DRD2 antagonist, ONC-206, which binds DRD2 with increased affinity. We tested three different MB cell lines with varied levels of DRD2 expression against these drugs, and consistently observed increased cell death at lower doses of ONC-206 compared to ONC-201. Following literature reports about the mechanism of action of ONC-201, we also evaluated the role of ClpP gene in MB cell lines. ClpP is a mitochondrial protease that has been shown to directly bind ONC 201. We observed a decrease in the expression of this gene after treatment of MB cell lines with ONC-206. Current studies are focusing on exploring the mechanism by which ONC-206 affects MB growth and metastasis. Dissecting this mechanism will be pivotal in predicting the role of this small molecule as a pre-clinical therapeutic for MB treatment.
Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance
Authors: Yan Xu, Matthew Ho, Mehmet Kemal Samur, Kenneth Wen, Shuhui Deng, Lanting Liu, Tengteng Yu, Zuzana Chyra, Sanika Derebail, Kenneth C. Anderson, Lugui Qiu, Mariateresa Fulciniti, Nikhil C. Munshi
Journal: Blood (2019)
Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
Authors: Persis J Amrolia, Robert Wynn, Rachael E Hough, Ajay Vora, Denise Bonney, Paul Veys, Robert Chiesa, Kanchan Rao, Liz Clark, Muhammad Al-Hajj, Shaun P Cordoba, Shimobi Onuoha, Ekaterini Kotsopoulou, Nushmia Z Khokhar, Martin Pule, Vijay G R Peddareddigari
Journal: Blood (2019)
Progression of Central Nervous System Vasculopathy in Young Adults with Sickle Cell Anemia
Authors: Grace Champlin, Scott Hwang, Guolian Kang, Juan Ding, Jeremie H. Estepp, Kenneth I. Ataga, Curtis L. Owens, Justin Newman, Lisa M. Jacola, Allison A. King, Robert Davis, Winfred Wang, Jane S. Hankins
Journal: Blood (2019)
SCIDOT-21. IMPROVING DRUG DELIVERY TO GLIOBLASTOMA BY TARGETING CANONICAL WNT/β-CATENIN SIGNALING IN THE BLOOD-BRAIN BARRIER
Authors: Amelie Vezina, Sadhana Jackson
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Glioblastoma (GBM) patient survival and therapy response is greatly hindered by the presence of invasive glioma stem cells (GSC) and the blood-brain barrier (BBB) which limits effective drug delivery. WNT/beta-catenin signaling is important in the development and maintenance of the BBB by mediating transcription of growth factors, multidrug resistance proteins, and junctional proteins. In WNT-subtype medulloblastoma, activating mutations of beta-catenin lead to reciprocal secretion of WNT antagonists such as WIF1 and DKK1 into the tumor microenvironment. These WNT antagonists can act upon the surrounding endothelium and induce a leaky BBB. Therefore, we hypothesize that pharmacological inhibition of WNT/beta-catenin signaling in brain endothelial cells will decrease BBB integrity, enabling enhanced paracellular drug delivery to infiltrative GSCs. METHODS We recapitulated the WNT-medulloblastoma phenotype in GBM by activating WNT/beta-catenin signaling in primary human GSCs, inducing secretion of downstream WNT antagonists. Conditioned-media (CM) from GSCs was then applied to human brain microvascular endothelial cells (HBMEC) to indirectly inhibit WNT signaling. Additionally, we directly inhibited WNT/beta-catenin signaling in HBMECs with the small molecule inhibitor ICG-001. Endothelial cell-cell interaction was measured by electrical impedance using the ACEA xCELLigence system. Fenestration and junctional expression were evaluated by immunoblotting and immunofluorescence. RESULTS ICG-001 or WNT-GSC-CM, but not control GSC-CM, upregulated fenestration related protein, PLVAP, and downregulated junctional proteins claudin-5, ZO-1, and VE-Cadherin in HBMECs. Endothelial cell-cell interaction was transiently decreased by ICG-001 or WNT-GSC-CM. Pre-clinical studies are underway to evaluate the functional impact of WNT/beta-catenin inhibition on BBB integrity and permeability in rodent glioma models. Altogether, these results support targeting WNT/beta-catenin signaling in brain endothelial cells to enhance drug delivery to CNS tumors. CONCLUSION Modulation of intratumoral Wnt/beta-catenin signaling, particularly in highly resistant GSCs, may enhance chemotherapy drug delivery, potentially expanding the drug portfolio and improving the prognosis of GBM.